The Discounted Cash Flow (DCF) valuation of Prostatype Genomics AB (PROGEN.ST) is (1,577,394.50) SEK. With the latest stock price at 10.80 SEK, the upside of Prostatype Genomics AB based on DCF is -14605604.6%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 4.8% - 6.2% | 5.5% |
| Long-term Growth Rate | 3.0% - 4.6% | 3.8% |
| Fair Price | (10,651,585.73) - (857,271.85) | (1,577,394.50) |
| Upside | -98625893.8% - -7937802.3% | -14605604.6% |